Ligand 10-Q Details Q3 Loss, 51% Royalty Growth and $460M Notes Now Current
LGND sits 84% above its 52-week low of $175.89.
Summary
Ligand's Q3 10-Q shows royalties up 51% to $70.3 million but a $28.5 million GAAP loss on XOMA deal costs and Pelthos mark-to-market, plus $460 million of 2030 Notes reclassified to current liabilities after the conversion trigger was met.
Key Events · Earnings and Guidance · LGND
-
Q3 GAAP Swing to Loss
Total revenues and income fell 32% to $78.7 million and net loss was $28.5 million (-$1.43 per share) versus net income of $117.3 million ($5.99) a year earlier, largely on the absence of last year's $53.1 million Pelthos divestiture gain.
-
Royalties Up 51% on XOMA
Royalties reached $70.3 million from $46.6 million, including $7.0 million from Ojemda, $3.6 million from Vabysmo and $1.7 million from Miplyffa acquired with XOMA on July 14, 2026.
-
XOMA Costs Hit G&A
General and administrative expense rose 155% to $72.6 million, including $14.2 million of XOMA transaction costs, $10.8 million of post-combination compensation and $7.6 million of severance.
-
2030 Notes Now Current
The conversion condition was met for the 30 trading days ended September 30, 2026, so the $460.0 million principal (carrying value $448.3 million) moved to current liabilities; holders may convert through December 31, 2026 and no notes had been submitted.
Analysis · LGND · Life Sciences
The headline numbers were already out on October 29, but the full 10-Q carries the balance-sheet story: royalties rose 51% to $70.3 million on the newly acquired XOMA assets, yet GAAP swung to a $28.5 million loss because of $14.2 million of XOMA deal costs, $10.8 million of post-combination compensation, $7.6 million of severance and a $35.7 million non-cash mark-to-market hit on the Pelthos stake. More consequential for the balance sheet, the 2030 Notes' conversion trigger was met, so $460 million of principal moved into current liabilities — holders can convert through December 31, 2026, and the company says it can settle the principal in cash. Cash and investments fell to $447.4 million from $733.5 million after the $887 million XOMA purchase, leaving the $124.4 million revolver untouched.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $324.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $175.89 to $326.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.